- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GEOPHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 52,50 | -0,34 % | Could Ionis Pharmaceuticals (IONS) Stock Become a Biotech Powerhouse as its Commercial Pipeline Takes Off? | ||
| CSPC PHARMA | 1,090 | +1,45 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2069 INJECTION FOR WEIGHT MANAGEMENT IN ADULT PATIENTS WITH OVERWEIGHT OR ... | ||
| SELLAS LIFE SCIENCES | 11,400 | 0,00 % | When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges | ||
| MADRIGAL PHARMACEUTICALS | 463,70 | +0,56 % | Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off | ||
| ACADIA PHARMACEUTICALS | 25,810 | +2,67 % | Acadia Pharmaceuticals Inc.: Europäische Kommission erteilt Zulassung für DAYBU (Trofinetid) als erste und einzige Therapie für neurobehaviorale Symptome des Rett-Syndroms in der Europäischen Union | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) hat heute bekannt gegeben, dass die Europäische Kommission (EK) die Marktzulassung für DAYBU (Trofinetid) zur Behandlung neurobehavioraler Symptome des Rett-Syndroms... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| OPUS GENETICS | 3,180 | -0,62 % | Citizens reiterates Opus Genetics stock rating on Viatris partnership potential | ||
| SAVARA | 4,533 | -3,68 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 3,380 | 0,00 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update | NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 0,868 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP | August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa"... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,025 | +2,04 % | NEURIZON THERAPEUTICS LIMITED: Application for quotation of securities - NUZ | ||
| CIPHER PHARMACEUTICALS | 8,700 | 0,00 % | Cipher Pharmaceuticals verfehlt Umsatzprognose für Q2 2026, Aktie legt dennoch zu | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| VASO | - | - | Vaso Corporation Announces Financial Results for Second Quarter of 2026 | PLAINVIEW, N.Y., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a business portfolio in professional sales services and proprietary non-invasive... ► Artikel lesen |
GEOPHARMA INC gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GEOPHARMA INC finden Sie auf Wallstreet Online.